AI Trends

Isomorphic Labs Completes $5 Billion Series C Funding, Doubling Its Previous Round

WallstreetcnUpdated Nov 18 15:45

AI summary

Isomorphic Labs, Alphabet's AI drug discovery company, announced on November 17 that it had completed a $5 billion Series C funding round, co-led by Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz and Alphabet. This round comes about six months after its $2.1 billion Series B funding in May of this year, with the scale more than doubling; the funds will be used to advance AI-driven new drug design and R&D. According to Dealroom data, AI drug discovery startups have raised a cumulative $23.2 billion in 2026.

Why read this

AI score 61

The funding scale doubled compared with the previous round, and the article provides the use of funds and overall financing data for the AI drug discovery sector, which can be used to gauge the pace of capital's bets on this direction.

Topics

Tags

Body · AI translation

Google parent company Alphabet's AI drug discovery startup Isomorphic Labs has completed a $5 billion Series C funding round, setting a new record for a single round of financing in the AI drug discovery field and highlighting the capital market's strong bet on the AI-driven new drug R&D track.

According to CNBC, Isomorphic Labs announced on Tuesday (November 17) that it had completed a $5 billion Series C funding round, led jointly by Greenoaks and Sequoia Capital, with Andreessen Horowitz participating and Alphabet also taking part. The funds raised will be used to advance AI-driven new drug design and R&D.

This funding round comes only about six months after Isomorphic Labs' previous round. The company completed a $2.1 billion Series B round in May this year, and the Series C round is more than double the size of the previous round. At the same time, this round comes only about three and a half months after the company's founder and former Google DeepMind CEO Demis Hassabis stepped down as DeepMind CEO.

Business layout: proprietary drug design engine and candidate pipeline

Isomorphic Labs is building a proprietary AI drug design engine and therapeutic candidate pipeline, and the company says the system will help it develop next-generation drugs. The company's core directions include building foundational biological models, deepening understanding of systemic diseases, and advancing its first therapeutic programs into clinical trials.

Isomorphic Labs was spun out of DeepMind in 2021 by Demis Hassabis, who has served as CEO since the company's founding. DeepMind is Google's AI lab, co-founded by Hassabis, and Google acquired it in 2014. This year, Hassabis stepped down from the DeepMind CEO position to focus on Isomorphic Labs.

In a statement, Hassabis said: "When we founded Isomorphic, we firmly believed that biology could be understood and modeled at the most fundamental molecular level, and that AI could fundamentally accelerate it." He added that this funding round will accelerate the company's progress in building foundational biological models, deepening understanding of systemic diseases, and advancing its first therapeutic programs toward clinical trials, with the aim of bringing tangible impact to patients.

The report said that Isomorphic Labs' massive funding reflects the capital boom across the entire AI pharmaceutical track. According to data from deal-tracking platform Dealroom, AI drug discovery startups have raised a cumulative $23.2 billion in 2026, a record high.

Several tech giants are also accelerating their presence in this field. Anthropic announced in June this year that it was launching an AI drug R&D project; OpenAI reached a partnership with Novo Nordisk in April this year to jointly explore the application of AI in new drug R&D. Risk warning and disclaimer

Markets carry risks, and investment requires caution. This article does not constitute personal investment advice and does not take into account the specific investment objectives, financial situation or needs of individual users. Users should consider whether any opinions, views or conclusions in this article are suitable for their particular circumstances. Investment based on this is at the user's own risk.

Source

Wallstreetcn